Avadel: Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

DUBLIN , April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24 th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET . A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days following the conference. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel's commercial product, LUMRYZ , was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com. Investor Contact: Austin Murtagh Precision AQ Austin.Murtagh@precisionAQ.com (212) 698-8696 Media Contact: Lesley Stanley Real Chemistry lestanley@realchemistry.com (609) 273-3162 Source: Avadel Pharmaceuticals plc 2025 GlobeNewswire, Inc., source Press Releases DUBLIN , April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24 th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET . A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days following the conference. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel's commercial product, LUMRYZ , was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com. Investor Contact: Austin Murtagh Precision AQ Austin.Murtagh@precisionAQ.com (212) 698-8696 Media Contact: Lesley Stanley Real Chemistry lestanley@realchemistry.com (609) 273-3162 2025 GlobeNewswire, Inc., source Press Releases